According to ADMA Biologics
's latest financial reports the company's current revenue (TTM ) is HK$2.97 Billion. In 2023 the company made a revenue of HK$2.01 Billion an increase over the revenue in the year 2022 that were of HK$1.20 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2024 (TTM) | HK$2.98 B | 48.1% |
2023 | HK$2.01 B | 67.52% |
2022 | HK$1.20 B | 90.74% |
2021 | HK$0.63 B | 92.84% |
2020 | HK$0.32 B | 43.19% |
2019 | HK$0.22 B | 71.85% |
2018 | HK$0.13 B | -25.2% |
2017 | HK$0.17 B | 115.1% |
2016 | HK$82.67 M | 48.6% |
2015 | HK$55.63 M | 21.25% |
2014 | HK$45.88 M | 92.89% |
2013 | HK$23.78 M | 174.46% |
2012 | HK$8.66 M | |
2011 | N/A | |
2010 | N/A |